The U of Nebraska recently started a clinical trial to evaluate...

The U of Nebraska recently started a clinical trial to evaluate Gilead's Remdesivir to treat COVID-19, sponsored by the National Institutes of Health (NIH/NIAID).
However, it has not proven to be beneficial yet:
"“We urgently need a safe and effective treatment for COVID-19. Although Remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes,” said NIAID Director and U.S. Coronavirus Task Force member Anthony S. Fauci, M.D."
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins

Contrast that with Mesoblast's statement today (excerpt):
"Remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19
infection. This is supported by recently published results from an investigator-initiated clinical study conducted in
China which reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated
patients with severe COVID-19 pneumonia."

My conclusion:
1) Dr. Itescu would not release today's PR unless he is pretty sure Remestemcel-L works. I believe he is not trying to simply get on the COVID-19 cure bandwagon to gain market attention. The man is conservative.
2) Gilead's Remdesivir is unproven so far, from Anthony Fauci's statement.

Advantage Mesoblast.